+44 (0) 845 0 66 33 00 | info@rotapharm.co.uk Home Company Products Contact Drug Safety The main objective of WM Ophthalmics company is to provide patients and physicians with safe and effective medicinal products (MPs). When developing new medicinal products (MPs), efficacy and safety are evaluated when carrying out clinical trials (CTs). Nevertheless, clinical trials (CTs) do not permit to evaluate completely the safety of medicinal products (MPs) and to identify all the adverse reactions (ARs) which may develop in the course of treatment: clinical trials are carried out in a limited number of patients, during limited time under the specially created conditions. Elderly patients, patients with concomitant diseases, pregnant and breastfeeding women, children are not enrolled in studies in most cases. Due to this, the information on long-term administration of medicinal products, drug-to-drug interaction results, peculiarities of usage in elderly people, children, pregnant women, development of rare (ARs) can be obtained at the stage of clinical usage of medicinal products from the medical staff which monitors over patients in the course of treatment, and from the patients, administering this medicinal product. Information gathering on medicinal product usage safety permits the company to obtain and furnish patients and physicians with new, reliable information on medicinal product safety; consequently, this helps physicians to make a correct prescription and to control better patients’ therapy. This permits patients to identify adverse reactions at the early development stages, and to adjust the therapy on time. A continuous monitoring of medicinal product safety after their market launch makes an integral part of our obligations towards patients and medical staff. Pharmacovigilance is such an activity that carries out identification, evaluation and prevention of adverse events (AEs). Reports on adverse events (AEs) from medical, pharmaceutical professionals and patients represent an important source of information on the safety of medicinal products. Adverse Event Report © 2017 Rotapharm - Pharmaceutical Company. All Rights Reserved.